#MindMed
LightNews LightNews
unhappinesspod.bsky.social
🚨NEW EPISODE🚨 How do perception and language shape subjectivity? What makes an experience ineffable? And can LSD offer new prospects for treating MDD and GAD? We're joined by @dankarlin.com of MindMed to talk new research trials, neurobiology, and more! www.buzzsprout.com/2131830/epis...
121: LSD: Subjectivity, Ineffability, and Mental Health feat. Dan Karlin - Ordinary Unhappiness
Abby and Patrick continue their series on psychedelics via an in-depth interview with Dr. Dan Karlin. Karlin is a psychiatrist and Chief Medical Officer at MindMed, where he oversees clinical trials u...
www.buzzsprout.com
November 8, 2025 at 3:04 PM
4040rec.bsky.social
#mentalhealth #PsychedelicInspiredMedicine #MindMed #MM120 #anxietydisorder #GeneralisedAnxietyDisorder #GAD #GADtreatment #MM120ODT #lysergideDtartrate #LSD #clinicaltrialparticipants #Voyagestudy #GADpatients #BreakthroughTherapyDesignation #Panoramastudy
pharmatimes.com/news/mindmed...
MindMed begins phase 3 study of MM120 for anxiety disorder - PharmaTimes
First patient dosed in landmark trial for GAD treatment
pharmatimes.com
December 19, 2024 at 11:53 AM
wealthwise-dca.bsky.social
MindMed Doses First Patient in LSD Anxiety Treatment Trial

Video: youtube.com/shorts/Ewhvi...

#MNMD #MNMDStock #MindMed #MindMedStock #LSDTreatment #MM120 #PsychedelicTreatment #Anxiety #AnxietyTreatment #AnxietyPsychedelics #PsychedelicsAnxiety #LSDAnxietyTreatment #MindMedVoyager
December 17, 2024 at 5:00 PM
josh-hardman.bsky.social
New Association Launches to Expand Patient Access to Psychedelic Medicines

Founding members include Compass, B. More, Lykos Therapeutics and MindMed.

The group's Scientific Advisors include Peter Hendricks, Paul Huston, Sandeep Nayak and Jennifer Jones.

www.psychedelicsrx.org/new-associat...
New Association Launches to Expand Patient Access to Psychedelic Medicines  - Association for Prescription Psychedelics
Organization Will Educate Policymakers and Advocate for the Development of Safe and Effective Prescription Psychedelics
www.psychedelicsrx.org
November 20, 2024 at 11:06 AM
prismmediawire.bsky.social
$MNMD MindMed (NASDAQ: MNMD) Q3 Snapshot: Advancing Three Phase 3 Trials with Ample Cash
MNMD Q3 Snapshot: Advancing Three Phase 3 Trials with Ample Cash
New York, November 08, 2024 - PRISM MarketView - MindMed (NASDAQ: MNMD) reported its third quarter 2024 financial results and provided significant business updates, highlighting its progress towards…
buff.ly
November 8, 2024 at 4:01 PM
marketwirenews.com
NEWS: ( NASDAQ: #MNMD ) MindMed to Participate in September Investor Conferences

#StockMarket #News
September 4, 2024 at 5:30 PM
stocktitan.net
#MNMD MindMed to Be Added to the Nasdaq Biotechnology Index

https://www.stocktitan.net/news/MNMD/mind-med-to-be-added-to-the-nasdaq-biotechnology-gao9v6bzu1b0.html
MindMed Joins Nasdaq Biotech Index After Landmark Year of $250M Funding and Clinical Advances
MindMed achieves major milestone with Nasdaq Biotech Index inclusion, following successful $250M fundraising and expansion of clinical pipeline for anxiety and depression treatments.
www.stocktitan.net
December 19, 2024 at 12:00 PM
viawesome.bsky.social
Cybin, MindMed are set to launch expanded human studies after recent trial setbacks for Lykos, Compass.
Can Canada’s psychedelic drug developers shake off the sector's bad trip?
Cybin, MindMed are set to launch expanded human studies after recent trial setbacks for Lykos, Compass.
dlvr.it
November 14, 2024 at 2:09 AM
nasdaq.activitypub.awakari.com.ap.brid.gy
MindMed Announces New Employee Inducement Grants NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company devel...

#Business #Wire #News #Releases #PMN #Press #Releases #BW

Origin | Interest | Match
MindMed Announces New Employee Inducement Grants
NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candi…
financialpost.com
December 1, 2025 at 9:25 PM
thedopedealer.bsky.social
Hop on your Bicycle, anxiety sufferers, MindMed is seeking volunteers for LSD testing!
Will THEIR version be approved?
What are the implications?
Watch The Dope-Dealer break it down.

#anxiety #lsd #acid #drugresearch #psychedelicassistedtherapy #news
youtu.be/ZlZW5n5h7Uk
MindMed dosed the first LSD patient in treatment being tested for generalized anxiety disorder.
Can LSD Cure Anxiety? Mind expanding mental health driven company MindMed has officially dosed the first patient in Panorama, its second, phase 3 clinical trial evaluating MM120, a patented lysergide, or (LSD) treatment being tested for generalized anxiety disorder. Their previous Voyage study compa
youtu.be
April 11, 2025 at 8:35 PM
nasdaq.activitypub.awakari.com.ap.brid.gy
MindMed Announces New Employee Inducement Grants NEW YORK — Mind Medicine (MindMed) Inc. (NASDA...

https://financialpost.com/pmn/business-wire-news-releases-pmn/mindmed-announces-new-employee-inducement-grants-5

#Business #Wire #News #Releases #PMN #Press #Releases #BW

Result Details
MindMed Announces New Employee Inducement Grants
NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candi…
financialpost.com
May 19, 2025 at 8:57 PM
owenmuir.bsky.social
Been In the AI game since before it was cool

psychedelicalpha.com/news/mindmed...
MindMed Announces Strategic Research Collaboration with Sphere Health - Psychedelic Alpha
NEW YORK, Oct. 5, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies…
psychedelicalpha.com
September 21, 2025 at 11:57 AM
richharidy.bsky.social
Considering the phase 2 LSD for anxiety study has been published and is in the news a bit right now, here's a piece from last year where I spoke to the CMO of MindMed about the trial's somewhat unique protocol. Bit more detail here about how the dose sessions worked than in the actual study.
Some psychedelic medicine developers want to ditch the therapy aspect. What could go wrong?
Are drugs like psilocybin and MDMA still safe and effective in the absence of psychotherapy?
www.salon.com
September 7, 2025 at 10:21 PM
taxman77.bsky.social
He just rips people off. Look at Mindmed. That was a total sham company.
December 28, 2024 at 5:26 PM
stocktitan.net
#MNMD MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

#investing #news #stocks

https://www.stocktitan.net/news/MNMD/mind-med-scientific-presentations-at-american-college-of-8nh3f5tnanzw.html
MindMed Showcases Breakthrough LSD Treatment Data for Anxiety Disorder at Major Congress
MindMed presents compelling Phase 2b clinical data for MM120, its novel LSD-based therapy showing rapid and lasting effects in treating generalized anxiety disorder.
www.stocktitan.net
December 11, 2024 at 12:00 PM
news-feed.bsky.social
@Matt_Turnerr: Psychedelics 🤝🏻 Stocks

Investors are once again betting that companies like MindMed and Atai will be big beneficiaries if drugs like LSD and MDMA can finally gain regulatory acceptance in the medical industry https://t.co/QMBdLMZ48s
March 28, 2024 at 3:33 PM
patesalo-e.bsky.social
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT) - Yahoo… https://news.google....
July 17, 2024 at 11:10 AM
sketchynews.net
[New York Post]Single dose of LSD can cut anxiety in half within weeks: 'Breakthrough' study - New York Post Just 100 micrograms of MM120 led to a 48% rate of remission from generalized anxiety disorder after 12 weeks, MindMed reported.
March 10, 2024 at 4:16 AM
burnabynow.bsky.social
Cybin, MindMed are set to launch expanded human studies after recent trial setbacks for Lykos, Compass.
Can Canada’s psychedelic drug developers shake off the sector's bad trip?
Cybin, MindMed are set to launch expanded human studies after recent trial setbacks for Lykos, Compass.
dlvr.it
November 14, 2024 at 2:03 AM
piquenews.bsky.social
Cybin, MindMed are set to launch expanded human studies after recent trial setbacks for Lykos, Compass.
Can Canada’s psychedelic drug developers shake off the sector's bad trip?
Cybin, MindMed are set to launch expanded human studies after recent trial setbacks for Lykos, Compass.
dlvr.it
November 14, 2024 at 2:04 AM
psymposia.bsky.social
Definium is MindMed, they just changed their name.

www.psymposia.com/magazine/min...
MindMed’s CEO Jamon “JR” Rahn Wants Nothing To Do With Those Psychedelic Decrim People
"I want nothing to do with those kinds of folks who want to decriminalize psychedelics,” Rahn told Forbes."
www.psymposia.com
September 16, 2026 at 9:37 PM
josh-hardman.bsky.social
- Reflecting on UW Madison’s Fourth Annual Psychedelic Symposium

- MindMed Doses First Patient in Phase 3 LSD Program

- Beckley Psytech Shares Small Cut of Data from Phase 2a Study of IV Psilocin in MDD

- Psilocybin for COVID Clinicians

- & more…

psychedelicalpha.com/news/p%ce%b1...
Pα+ Psychedelic Bulletin #183: UW Madison’s Psychedelic Symposium; MindMed Doses First Phase 3 Patient; Beckley’s IV Psilocin Readout; Psilocybin for COVID Clinicians - Psychedelic Alpha
In this Issue Add a header to begin generating the table of contents Members of the Psychedelic Alpha team Josh Hardman and Noah Smith, as well as Editor-at-Large Graham Pechenik, had a great time…
psychedelicalpha.com
December 18, 2024 at 6:00 PM
blackwingbear.bsky.social
Psychedelic drug developer MindMed set for listing on Nasdaq Biotechnology Index
MindMed's lead drug candidate is an LSD-like therapeutic used to treat anxiety
mugglehead.com
January 2, 2025 at 8:31 PM
twiggs462.bsky.social
MindMed is developing MM120, the tartrate salt form of lysergide, for GAD and MDD and is exploring its potential applications in other serious brain health disorders. MM120 (lysergide D-tartrate or LSD) is a synthetic ergotamine belonging to the group of classic psychedelics.

MindMed.co
November 10, 2024 at 3:01 PM
daverino.bsky.social
"A single dose of the psychedelic drug LSD seems to reduce anxiety without lasting side effects. “Ours is the first modern trial to look specifically at LSD, or any psychedelic, for generalised anxiety disorder,” says Dan Karlin at biotech company MindMed in NY"
www.newscientist.com/article/2495...
A single dose of LSD seems to reduce anxiety
About half of people with generalised anxiety disorder don’t respond to common treatments with antidepressants – but psychedelics may offer relief
www.newscientist.com
September 5, 2025 at 5:06 AM